VX-150 is under clinical development by Vertex Pharmaceuticals and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VX-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VX-150 is under development for the treatment of chronic pain caused by osteoarthritis and small fiber neuropathy, as well as acute pain following bunionectomy surgery. It is administered orally and intravenously. The drug candidate acts by targeting voltage-gated sodium channel, NaV 1.8.
Vertex Pharmaceuticals overview
Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.
For a complete picture of VX-150’s drug-specific PTSR and LoA scores, buy the report here.